Inovio Pharmaceuticals, Inc.
INO
$2.04
$0.094.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -44.19% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -44.19% | |||
| Cost of Revenue | -9.75% | 24.88% | |||
| Gross Profit | 9.39% | -25.51% | |||
| SG&A Expenses | -5.12% | 18.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.09% | 22.60% | |||
| Operating Income | 7.85% | -22.98% | |||
| Income Before Tax | -19.42% | -1.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.42% | -1.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.42% | -1.61% | |||
| EBIT | 7.85% | -22.98% | |||
| EBITDA | 7.90% | -23.69% | |||
| EPS Basic | -18.76% | 21.08% | |||
| Normalized Basic EPS | -18.19% | 19.10% | |||
| EPS Diluted | -18.76% | 21.08% | |||
| Normalized Diluted EPS | -18.19% | 19.10% | |||
| Average Basic Shares Outstanding | 0.56% | 28.74% | |||
| Average Diluted Shares Outstanding | 0.56% | 28.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||